← Back

Wire · opportunities

FDA approves first drug shown to extend survival in infantile-onset Niemann-Pick disease type C

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mlq.ai →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The FDA approved Lembaz (adrabetadex) as the first drug to extend survival in infantile-onset Niemann-Pick disease type C, reducing death risk by 55% in treated patients. The drug, given by spinal canal injection, carries a hearing loss warning and is expected to be commercially available in December.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Nov 2026 and 18 Nov 2026.

◆ ◆ The Wire takeaway

You now have a clear market opening in rare genetic diseases after Lembaz sets a new survival benchmark for infantile Niemann-Pick type C. Prepare to engage specialists and advocacy groups as early commercial access will focus on this extremely rare patient group.

◆ Coverage

5 sources · first reported 17 Nov 2026 · latest 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseasenpcsurvival-extensiondrug-safety